PRESS RELEASE

THE NATIONAL RESEARCH AND INNOVATION AGENCY

NO: 010/SP/HM/BKPUK/I/2022

RT LAMP, Research Collaboration between BRIN and Industry

The method of Reverse Transcription Loop-Mediated Isothermal Amplification (RT LAMP) is one of the results of research by the researchers of the National Research and Innovation Agency (BRIN) to support the handling of the Covid-19 pandemic. This method is expected to improve the detection capability so that Covid-19 virus can be detected more quickly and help control its spread. The results of this research will, in addition to providing accumulated research capabilities for the Research Team, increase the number of medical devices developed by Indonesian researchers

Jakarta, 21 January 2022. Research on development of RT-LAMP has started since the beginning of the pandemic. BRIN has supported the endeavor from the beginning until it gets a regular distribution permit as at this time. The hard work of researchers and industry partners who have dedicatedly carried out this research deserves appreciation.

Head of BRIN, Laksana Tri Handoko, said that this experience is important not only for the current pandemic, but also serves as the capital to develop various other detection tools in the future. “This will include completing it with a sampling method through saliva, so you do not have to use a swab through the nose which is uncomfortable,” he said.

The head of BRIN is committed to continuing to facilitate researchers so they can develop various innovations, and meet applicable regulatory standards.

BRIN’s Acting Deputy for Research and Innovation Utilization, Mego Pinandito, emphasized that having a Regular Distribution Permit Certificate which is valid for five years, shows an extraordinary achievement. “This is not an Emergency Distribution Permit. This regular distribution permit boosts confidence in the ability of researchers, in addition to, of course supports from various parties and related institutions, “he said.

Mego hopes that, after obtaining a license from BRIN and this distribution permit, it is hoped that PT. Biosains Medika Indonesia can immediately produce and market these products. It is also hoped that registration of this product with the LKPP electronic catalog, will support the marketing of the product, especially procurement by government agencies.

Director of PT Biosains Medika Indonesia, Rifan Ahmad, said that the testing applications for Covid 19 that presently are widely known and understood by the public are rapid antigen tests, rapid antibody tests and real time PCR. “The RT LAMP application is considered a relatively new examination method, both for the screening process and making diagnosis,” said Rifan.

Rifan explained, under Regulation of the Minister of Health Number HK.01.07/MENKES/4642/2021, the types of NAAT methods used to carry out COVID-19 examination include, Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) as the main standard for confirming diagnosis of COVID-19 and Loop Mediated Isothermal Amplification (LAMP).

Research Collaboration

PT Biosains Medika Indonesia, explained Rifan, is a domestic investment distributor company that has a vision to advance the sectors of research and industrial development in the country. “One of the works that PT Biosains Medika Indonesia is currently doing is to produce and market QiLamp products as a result of research and development collaboration with BRIN,” he said. “The development of QiLamp, as a product that uses the RT LAMP method, is not limited to Covid, but may also be used for the diagnosis of other diseases,” added Rifan.

The research collaboration with BRIN, said Rifan, was initiated in mid-2020, shortly after the COVID pandemic began to develop in Indonesia. BRIN plays a role in research, development and technology transfer. “PT Biosains Medika Indonesia acts as the party that carries out research and development, registration of distribution permit, product brands, and production and commercialization of the kits. The cooperation pattern is partnership and joint ownership of intellectual property (KI) in the form of Patent No: P00202110864 and technology transfer through an exclusive license,” said Rifan.

Based on the results of sensitivity and specificity tests, the QiLamp kit got the test result of 100% for both aspects, compared to the current method of gold standard, namely Realtime PCR. “The RT-LAMP technology in theory uses the same components as for real time PCR, one of which using a primer to detect DNA similarity, so that the characteristics of the results are similar to that of real time PCR, but with an easier and more economical method,” concluded Rifan.